Method of treating cancer comprising a VEGF-B antagonist

  • US 8,822,644 B2
  • Filed: 08/02/2005
  • Issued: 09/02/2014
  • Est. Priority Date: 08/02/2004
  • Status: Active Grant
First Claim
Patent Images

1. An isolated anti-VEGF-B antibody that inhibits binding of VEGF-B to VEGFR-1 wherein the antibody binds human VEGF-B with a KD value of 1×

  • 10

    M or less, wherein said antibody comprises all six CDR sequences from the heavy and light chain variable regions of mAb 2H10 as set forth in SEQ ID NOs;

    5-10 in a human framework with a backmutation at position H73.

View all claims

    Thank you for your feedback